RxDoctor Payments Data

Keith Hickey, MD

Cardiovascular Disease · Slidell, LANPI 1538100078

Payments from drug & device makers

$7,200in general payments, 2019–2025

Across 471 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$939
  • Johnson & Johnson$918
  • Pfizer$822
  • Esperion Therapeutics, Inc.$387
  • Sanofi-aventis U.S. LLC$338
  • E.r. Squibb & Sons, L.L.C.$317
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$7,11299%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,200 in reported general payments places this provider in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$24,255
Medicare patients
109
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin259$253,942
OzempicSemaglutide181$195,293
EliquisApixaban115$131,503
XareltoRivaroxaban109$98,973
EntrestoSacubitril/Valsartan65$65,371
MounjaroTirzepatide54$64,345
FarxigaDapagliflozin Propanediol85$61,522
Repatha SureclickEvolocumab61$36,756
MultaqDronedarone Hcl15$24,472
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,584
CorlanorIvabradine Hcl24$13,747
VascepaIcosapent Ethyl17$13,037
VerquvoVericiguat13$12,679
Midodrine Hcl123$6,822
Metoprolol Succinate435$5,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$201$253,942259 claims
Novo NordiskOzempic$279$195,293181 claims
PfizerEliquis$822$131,503115 claims
Johnson & JohnsonXarelto$918$98,973109 claims
AstraZenecaFarxiga, Breztri Aerosphere$208$77,106110 claims
NovartisEntresto$939$65,37165 claims
Lilly USA, LLCMounjaro$77$64,34554 claims
Sanofi-aventis U.S. LLCMultaq$338$24,47215 claims
AmgenCorlanor$241$13,74724 claims
MerckVerquvo$247$12,67913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →